Clinical trial
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and…
NCT00139750 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00139750 |
|---|---|
| Title | 12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation |
| Official title | A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Drug |
| Interventions | CP-526, 555 (varenicline) |
| Enrollment | 600 |
| Start date | Dec 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | Jun 4, 2007 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: